Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

61. Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence

Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence | CADTH.ca Find the information you need Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical (...) Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Published on: August 20, 2012 Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from . [Optimal Use Report; Volume 1, Issue 2A]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Atrial fibrillation (AF) is the most common

CADTH - Health Technology Assessment2015

62. Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence

Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence | CADTH.ca Find the information you need Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical (...) Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Published on: August 20, 2012 Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from . [Optimal Use Report; Volume 1, Issue 2A]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Atrial fibrillation (AF) is the most common

CADTH - Health Technology Assessment2015

63. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin 26189039 2015 08 31 2015 11 16 2016 12 15 1879-1913 116 6 2015 Sep 15 The American journal of cardiology Am. J. Cardiol. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. 904-12 10.1016/j.amjcard.2015.06.016 S0002-9149(15)01532-5 We sought (...) to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin

EvidenceUpdates2015

64. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures

Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures 26010033 2015 07 07 2015 09 25 2015 07 07 2168-6114 175 7 2015 Jul JAMA internal medicine JAMA Intern Med Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. 1163-8 10.1001/jamainternmed.2015.1843 The risk of bleeding and recurrent venous thromboembolism (VTE) among patients receiving long-term warfarin sodium (...) therapy for secondary VTE prevention who require temporary interruption of anticoagulant therapy for surgery or invasive diagnostic procedures has not been adequately described. To describe the rates of clinically relevant bleeding and recurrent VTE among patients in whom warfarin therapy is interrupted for invasive procedures and compare these rates among patients who did and did not receive bridge therapy. A retrospective cohort study was conducted at Kaiser Permanente Colorado, an integrated health

EvidenceUpdates2015

65. Comparison of the Usefulness of Enoxaparin Versus Warfarin for Prevention of Left Ventricular Mural Thrombus After Anterior Wall Acute Myocardial Infarction

Comparison of the Usefulness of Enoxaparin Versus Warfarin for Prevention of Left Ventricular Mural Thrombus After Anterior Wall Acute Myocardial Infarction 25765590 2015 04 13 2015 06 26 2015 04 13 1879-1913 115 9 2015 May 01 The American journal of cardiology Am. J. Cardiol. Comparison of the usefulness of enoxaparin versus warfarin for prevention of left ventricular mural thrombus after anterior wall acute myocardial infarction. 1200-3 10.1016/j.amjcard.2015.02.007 S0002-9149(15)00696-7 Left (...) ventricular (LV) thrombus is one of the most common complications in patients with anterior acute myocardial infarction (AMI) and LV dysfunction. Although anticoagulation is frequently prescribed, data regarding the appropriate drug, duration, risks, and effect on echocardiographic indices of thrombus are lacking. Moreover, given the difficulty in obtaining adequate anticoagulation with warfarin, it is possible that short-term treatment with a more predictable agent would be effective. We randomized 60

EvidenceUpdates2015

66. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. BACKGROUND: Warfarin is the most widely used oral anticoagulant worldwide, but serious bleeding complications are common. We tested whether genetic variants can identify patients who are at increased risk of bleeding with warfarin and, consequently, those who would derive a greater safety benefit with a direct oral anticoagulant rather than warfarin. METHODS: ENGAGE (...) AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrillation were assigned to warfarin to achieve a target international normalised ratio of 2·0-3·0, or to higher-dose (60 mg) or lower-dose (30 mg) edoxaban once daily. A subgroup of patients was included in a prespecified genetic analysis and genotyped for variants in CYP2C9 and VKORC1. The results were used to create three genotype functional bins (normal, sensitive, and highly sensitive responders to warfarin

Lancet2015

73. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation 25687352 2015 06 15 2016 03 15 2016 11 25 1522-9645 36 23 2015 Jun 14 European heart journal Eur. Heart J. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. 1470-7 10.1093/eurheartj/ehv014 Edoxaban is an oral, once-daily factor Xa inhibitor that is non-inferior to well-managed warfarin in patients with atrial fibrillation (AF) for (...) the prevention of stroke and systemic embolic events (SEEs). We examined the efficacy and safety of edoxaban vs. warfarin in patients who were vitamin K antagonist (VKA) naive or experienced. ENGAGE AF-TIMI 48 randomized 21 105 patients with AF at moderate-to-high risk of stroke to once-daily edoxaban vs. warfarin. Subjects were followed for a median of 2.8 years. The primary efficacy endpoint was stroke or SEE. As a pre-specified subgroup, we analysed outcomes for those with or without prior VKA experience

EvidenceUpdates2015

74. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study.

The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. OBJECTIVE: To determine rates of major bleeding by level of kidney function for older adults with atrial fibrillation starting warfarin. DESIGN: Retrospective cohort study. SETTING: Community based, using province wide laboratory and administrative data in Alberta, Canada. PARTICIPANTS: 12,403 adults aged 66 years or more (...) , with atrial fibrillation who started warfarin treatment between 1 May 2003 and 31 March 2010 and had a measure of kidney function at baseline. Kidney function was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation and participants were categorised based on estimated glomerular filtration rate (eGFR): ≥ 90, 60-89, 45-59, 30-44, 15-29, <15 mL/min/1.73 m(2). We excluded participants with end stage renal disease (dialysis or renal transplant) at baseline. MAIN OUTCOME MEASURES: Admission

BMJ2015

75. Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin

Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin | Evidence (...) patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Article Text Aetiology/Harm Cohort study Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin John W Eikelboom , Jackie

Evidence-Based Medicine (Requires free registration)2015

76. Randomised control trial: Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin

Randomised control trial: Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin Article Text Therapeutics/Prevention Randomised control trial Using the Watchman

Evidence-Based Medicine (Requires free registration)2015

77. Cohort study: Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s

Cohort study: Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s Article Text Aetiology/Harm Cohort study Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during

Evidence-Based Medicine (Requires free registration)2015

78. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism 26403199 2016 01 28 2016 12 20 2016 12 30 0340-6245 115 2 2016 Jan Thrombosis and haemostasis Thromb. Haemost. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. 291-8 10.1160/TH15-04-0319 Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus (...) warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61-0.79), as was the incidence of the composite of MBEs and clinically

EvidenceUpdates2015

79. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. IMPORTANCE: While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions. OBJECTIVE: To determine whether a local strategy of mechanical left atrial appendage (LAA) closure was noninferior to warfarin. DESIGN, SETTING (...) event rates between treatment groups. INTERVENTIONS: Left atrial appendage closure with the device (n = 463) or warfarin (n = 244; target international normalized ratio, 2-3). MAIN OUTCOMES AND MEASURES: A composite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death, analyzed by intention-to-treat. RESULTS: At a mean (SD) follow-up of 3.8 (1.7) years (2621 patient-years), there were 39 events among 463 patients (8.4%) in the device group for a primary event

JAMA2014

80. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2014 11 18 2015 04 14 2016 10 25 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS (...) United States R01 HL126547 HL NHLBI NIH HHS United States R03 AG040631 AG NIA NIH HHS United States Comment Journal Article United States Ann Intern Med 0372351 0003-4819 0 Factor Xa Inhibitors 0 Morpholines 0 Thiophenes 12001-79-5 Vitamin K 5Q7ZVV76EI Warfarin AIM IM Eur Heart J. 2014 Jul 21;35(28):1864-72 24561548 Circulation. 2011 May 31;123(21):2363-72 21576658 Circulation. 2014 Jul 8;130(2):138-46 24895454 Atrial Fibrillation drug therapy Embolism prevention & control Factor Xa Inhibitors Female

Annals of Internal Medicine2014 Full Text: Link to full Text with Trip Pro